We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+13.63%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.76B
AUM Growth
+$122M
Cap. Flow
-$172M
Cap. Flow %
-6.22%
Top 10 Hldgs %
38.62%
Holding
217
New
37
Increased
33
Reduced
47
Closed
5

Top Buys

Rank Stock Value
1
ZTS icon
Zoetis
ZTS
+$17M
2
JNJ icon
Johnson & Johnson
JNJ
+$13.8M
3
NVO
Novo Nordisk
NVO
+$8.1M
4
ELV icon
Elevance Health
ELV
+$7.92M
5
TMO icon
Thermo Fisher Scientific
TMO
+$6.37M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$42.7M
2
PFE icon
Pfizer
PFE
+$40.8M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$30.9M
4
UNH icon
UnitedHealth
UNH
+$21M
5
LLY icon
Eli Lilly
LLY
+$17.4M

Sector Composition

Rank Sector Weight
1 Healthcare 93.74%
2 Real Estate 2.75%
3 Financials 0.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
26
Neurocrine Biosciences
NBIX
$18.7B
$26.1M 0.95%
212,630
-57,139
-21% -$6.48M
IDXX icon
27
Idexx Laboratories
IDXX
$44.1B
$25.6M 0.93%
102,403
-27,205
-21% -$6.6M
CNC icon
28
Centene
CNC
$30.1B
$24.2M 0.88%
333,738
-35,900
-10% -$2.49M
LLY icon
29
Eli Lilly
LLY
$1.03T
$23.2M 0.84%
216,442
-173,666
-45% -$17.4M
HUM icon
30
Humana
HUM
$44B
$23.2M 0.84%
68,487
-36,566
-35% -$11.9M
DHR icon
31
Danaher
DHR
$138B
$22.8M 0.83%
236,170
+18,612
+9% +$1.69M
BMY icon
32
Bristol-Myers Squibb
BMY
$132B
$22.7M 0.82%
366,064
-284,966
-44% -$16.9M
SGEN
33
DELISTED
Seagen Inc. Common Stock
SGEN
$21.5M 0.78%
279,417
– –
ZTS icon
34
Zoetis
ZTS
$31.9B
$20.8M 0.76%
227,415
+191,655
+536% +$17M
SAGE
35
DELISTED
Sage Therapeutics
SAGE
$20.3M 0.74%
143,614
– –
TEVA icon
36
Teva Pharmaceuticals
TEVA
$41.2B
$20.1M 0.73%
932,948
-150,895
-14% -$3.5M
OHI icon
37
Omega Healthcare
OHI
$15B
$19M 0.69%
579,785
– –
JAZZ icon
38
Jazz Pharmaceuticals
JAZZ
$16.2B
$18.6M 0.67%
110,452
– –
ENDP
39
DELISTED
Endo International plc
ENDP
$17.2M 0.62%
1,019,048
-59,366
-6% -$843K
BSX icon
40
Boston Scientific
BSX
$68.4B
$17.1M 0.62%
444,991
-12,594
-3% -$440K
AET
41
DELISTED
Aetna Inc
AET
$17M 0.62%
83,637
-13,485
-14% -$2.64M
SBRA icon
42
Sabra Healthcare REIT
SBRA
$5.38B
$16.8M 0.61%
724,606
– –
BDX icon
43
Becton Dickinson
BDX
$45.6B
$16.8M 0.61%
65,782
+11,480
+21% +$2.83M
ZBH icon
44
Zimmer Biomet
ZBH
$18.4B
$15.6M 0.57%
122,411
– –
ONC
45
BeOne Medicines Ltd
ONC
$33.4B
$14.8M 0.54%
85,755
+30,970
+57% +$5.21M
NVO
46
Novo Nordisk
NVO
$228B
$14.2M 0.52%
603,800
+332,000
+122% +$8.1M
ISRG icon
47
Intuitive Surgical
ISRG
$126B
$14.1M 0.51%
73,887
+3,450
+5% +$613K
BMRN icon
48
BioMarin Pharmaceuticals
BMRN
$11.7B
$13.6M 0.49%
140,538
– –
EW icon
49
Edwards Lifesciences
EW
$50B
$13.4M 0.48%
230,088
+31,263
+16% +$1.53M
NKTR icon
50
Nektar Therapeutics
NKTR
$2.41B
$13M 0.47%
14,165
+1,580
+13% +$1.35M
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Tekla Capital Management held 217 positions worth $2.76B, up 4.6% from $2.64B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management withdrew a net $172M in Q3 2018, closing 5 positions and reducing 47 holdings. Its most notable exit was Welltower Inc., an estimated $11.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Real Estate and Financials.

Against the trend, Tekla Capital Management opened a new position in Quest Diagnostics worth $4.21M.

  • Tekla Capital Management's largest Q3 2018 buy was Quest Diagnostics: 39,000 shares worth $4.21M.
  • Tekla Capital Management added most to Zoetis in Q3 2018, an estimated $17M increase.
  • Tekla Capital Management's biggest Q3 2018 reduction was Merck, cutting an estimated $42.7M.
  • Tekla Capital Management fully exited Welltower Inc. in Q3 2018, selling an estimated $11.9M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.76B portfolio in Q3 2018.
  • Tekla Capital Management opened 37 new positions and closed 5 in Q3 2018.
  • Tekla Capital Management's portfolio value rose 4.6% quarter-over-quarter to $2.76B.

Based on Tekla Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.